Future growth expectations in sales/revenue/volumes?

P&G aims for consistent high single-digit sales and profit growth, building on the past 10 years of performance. Feminine care category expected to grow at double-digit rates over the next 3 years. The quick commerce channel is rapidly expanding and currently growing at 2X, expected to continue driving FMCG growth. Rural and urban consumption show green shoots, with positive outlook supported by good monsoons and softening inflation. New product innovations and upgrades will continue to drive category and company growth. Long-term demand growth is supported by increasing penetration in both ru

Future growth expectations in earnings/operating earnings/profits/EPS?

P&G India delivered 7% sales growth and 19% operational profit growth in the last fiscal year, indicating strong momentum. Structural margins improved by approximately 400 basis points this year due to productivity and premium innovations. The company expects continued double-digit growth in key categories such as feminine care over the next 3 years. Productivity savings and operating efficiencies fuel reinvestment in product superiority, supporting margin expansion. Management emphasizes sustained long-term profit growth through innovation, trade-ups, and category growth. Investment

Procter & Gamble Hygiene and Health Care LtdQ1 FY25Personal Products

Procter & Gamble Hygiene and Health Care Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹6,851P/E: 28.1Market Cap: ₹22.2K CrSector: Personal Products

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 2 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

P&G aims for consistent high single-digit sales and profit growth, building on the past 10 years of performance.
Feminine care category expected to grow at double-digit rates over the next 3 years.
The quick commerce channel is rapidly expanding and currently growing at 2X, expected to continue driving FMCG growth.
Rural and urban consumption show green shoots, with positive outlook supported by good monsoons and softening inflation.
New product innovations and upgrades will continue to drive category and company growth.
Long-term demand growth is supported by increasing penetration in both rural and urban markets, especially in feminine care.
Continued focus on dynamic, integrated growth strategy focusing on superiority, productivity, and constructive disruption.
Productivity improvements and innovation will fuel sustainable balanced top- and bottom-line growth.

Margin guidance

Category 3

P&G India delivered 7% sales growth and 19% operational profit growth in the last fiscal year, indicating strong momentum.
Structural margins improved by approximately 400 basis points this year due to productivity and premium innovations.
The company expects continued double-digit growth in key categories such as feminine care over the next 3 years.
Productivity savings and operating efficiencies fuel reinvestment in product superiority, supporting margin expansion.
Management emphasizes sustained long-term profit growth through innovation, trade-ups, and category growth.
Investments in brand building and innovation may temporarily pressure margins (e.g., June quarter), but these are viewed as foundational for future equity and profit growth.
The integrated growth strategy, agility, and constructive disruption position P&G well to capitalize on evolving consumer needs and premiumization trends, supporting balanced top- and bottom-line growth and improving EPS over time.

See what Procter & Gamble Hygiene and Health Care Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or future fundraising plans through debt or equity for Procter & Gamble Hygiene and Health Care Limited. Key points related to financial matters include: - Focus on productivity improvements to fund superiority and reinvestments internally. - Structural margins improved by 400 basis points through productivity and innovation. - Deliberate choice to invest part of margins back into the business for brand awareness. - No explicit mention of raising funds via debt or equity. - The company has demonstrated consistent sales and profit growth without external fundraising. - The outlook is centered on organic growth and strategic partnerships rather than external capital raising. In summary, there is no indication or announcement of new fundraising through debt or equity in the provided transcript.

Order book

The transcript from the Procter & Gamble Hygiene and Health Care Limited Investors & Analysts Call does not provide any specific details regarding the current or expected order book or pending orders. Key highlights related to business performance, strategy, product innovation, market growth, and quick commerce were discussed, but there is no mention of order backlog, pending orders, or future order book status. - No specific information on current or expected order book or pending orders is disclosed in the transcript. - The focus of the call is on sales growth, strategy, product launches, category trends, and market outlook. - Growth highlights include sales up 7% to ₹4192 crore and operational profit up 19% year-over-year. - Quick commerce is growing rapidly at 2X but specific order metrics are not shared. For precise order book details, you may refer to official company filings or direct communication channels.

See what Procter & Gamble Hygiene and Health Care Ltd management said on order book — free account, 30 seconds.

Capex plans

The transcript does not explicitly mention specific current or future capex (capital expenditure) or strategic investments in numeric terms. However, related points include: - Continued investment in technology and data-driven approaches, including AI and machine learning for supply chain optimization (Supply 3.0) and automated quality checks. - Strategic investments in innovation, including new product launches like Whisper Ultra XL for Heavy Flow, Vicks Double Power Cough Drops, and Vicks VapoRub Steam Pods. - Ongoing productivity initiatives that generated savings (over Rs. 113 crores last year) to reinvest in product superiority and innovation. - Investments in expanding distribution reach and strengthening partnerships across traditional, modern retail, ecommerce, and quick commerce channels. - Commitment to sustainability initiatives linked with Extended Producers Responsibility and partnerships with municipalities and NGOs for waste management. - Organization development to enable agility and accountability supporting business growth. No direct capex figures or detailed capital investment plans disclosed in the transcript.

Track Procter & Gamble Hygiene and Health Care Ltd — get its next earnings analysis in your feed

How does Procter & Gamble Hygiene and Health Care Ltd rank vs peers in Personal Products?

Pro feature

ThisProcter & Gamble Hygiene and Health Care Ltd

Rev 4Mar 3

See where Procter & Gamble Hygiene and Health Care Ltd sits in Personal ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Procter & Gamble Hygiene and Health Care Ltd rank in Personal Products?

Compare Procter & Gamble Hygiene and Health Care Ltd against every Personal Products company (Q1 FY25) on revenue, margins and earnings-call signals.

View Personal Products leaderboard →

What Procter & Gamble Hygiene and Health Care Ltd's management said in earlier quarters

Others in Personal Products this season

Aakaar Medical (Q2 FY27)
Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) . Key investor presentation takeaways from Aakaar M
Recode Studios Ltd (Q4 FY26)
The company plans to sustain marketing spends at about 20% of revenue to support growth and brand visibility, implying continued focus on operating profits…
Godrej Consumer Products Ltd (Q2 FY27)
Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej
Colgate-Palmolive (India) Ltd (Q2 FY27)
1,692 crore, up 12.2% year-on-year from Rs. Key results statement takeaways from Colgate-Palmolive (India) Ltd's Q2 FY27 results statement — and how it ranks ag

Compare:vs Godrej Consumer Products Ltd vs Dabur India Ltd vs Cupid Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →